NAL ER
Sponsors
Trevi Therapeutics
Conditions
Healthy ParticipantsIdiopathic Pulmonary FibrosisRefractory Chronic Cough
Phase 1
A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants
CompletedNCT07015398
Start: 2025-06-30End: 2025-09-26Updated: 2025-10-10
NAL ER IPF Respiratory Function and Safety Study
CompletedNCT07036029
Start: 2025-08-21End: 2026-06-30Updated: 2026-08-03
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
CompletedNCT07487740
Start: 2026-02-27End: 2026-05-19Updated: 2026-08-21
Phase 2
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
CompletedNCT04030026
Start: 2019-10-29End: 2022-05-27Updated: 2025-05-29
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
CompletedNCT05962151
Start: 2023-11-30End: 2025-01-06Updated: 2026-03-30
Cough Reduction in IPF With Nalbuphine ER
CompletedNCT05964335
Start: 2024-02-06End: 2025-04-24Updated: 2026-06-26
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)
RecruitingNCT07671924
Start: 2026-06-22End: 2027-09-01Target: 100Updated: 2026-08-10